Symbols

MCK

McKesson·NYSE

--(--)

MCK fundamentals

MCK Q3 2026 Earnings

McKesson (MCK) released its earnings on Feb 4, 2026: revenue was 106.16B (YoY +11.40%), beat estimates; EPS was 9.34 (YoY +16.31%), beat estimates.

Revenue / YoY

106.16B

+11.40%

EPS / YoY

9.34

+16.31%

Report date

Feb 4, 2026

MCK Earnings Call Summary for Q3,2026

Revenue Growth Acceleration: Q3 revenue up 11% to $106.2B, driven by oncology (+37%) and biopharma services.
AI-Driven Efficiency: AI tools reduced DSCSA inquiries by 75%, with 100% service accuracy in Canada.
Margin Expansion: Operating profit up 13% to $1.7B; Prescription Tech margin improved 138bps YoY, oncology operating profit +57%.
Shareholder Returns: $680M share buybacks; TTM free cash flow $9.6B.
GLP-1 Momentum: Sequential revenue growth 7%, oral GLP-1 launches poised to expand market.
Regulatory Adaptation: Smooth IRA Part D implementation; MFN impact limited to 35% of oncology Medicare.

Earnings

EPS

Revenue

Revenue & Expenses

MCK has released its 2026 Q3 earnings report, with revenue of 106.16B, reflecting a YoY change of 11.40%, and net profit of 1.25B, showing a YoY change of 34.70%. The Sankey diagram below clearly presents MCK's revenue sources and cost distribution.

Key Indicators

McKesson (MCK) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

McKesson (MCK)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

McKesson (MCK)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

McKesson (MCK)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown